Intractable Pain
18
3
3
7
Key Insights
Highlights
Success Rate
70% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
16.7%
3 terminated out of 18 trials
70.0%
-16.5% vs benchmark
11%
2 trials in Phase 3/4
71%
5 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (18)
Periganglionic Resiniferatoxin for the Treatment of Intractable Pain Due to Cancer-induced Bone Pain
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
Managing Pain Using Optimized Sequences by Adjusting Parameters With Independent Current Control
Post Market Evaluation of Real World Outcomes and Durability to Support Implantable Inceptiv™ Spinal Cord Stimulation Therapy
MRI Evaluation of Spinal Cord Edema After CT-Guided Percutaneous Cordotomy in Cancer Pain Patients
Study to Evaluate Automated Intensity Management in Patients Undergoing a BSC SCS Temporary Trial
Intrathecal Morphine Administration Using Implantable Pump With Continuous or Programmable Flow
Prometra Post-Approval Study
Safety and Activity Study of Intrathecally Administered Ziconotide for Neuropathic Pain in Patients With Cancer
Multi-center Prospective Study Determining the Sustainability of Pain Relief and Psychosocial and Functional Responses When Utilizing a Multiple Waveform Enabled Neurostimulator
Efficacy of the Spinal Cord Stimulation System as Salvage Therapy
Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Ilera Specific Products
Transitioning to a Valve -Gated Intrathecal Drug Delivery System (IDDS)
Ketamine and Refractory Painful Care in a Palliative Unit
Behavioral Treatments for Chronic Pain
NP2 Enkephalin For Treatment of Intractable Cancer Pain
Prometra's Utilization in Mitigating Pain (PUMP)
Prometra's Utilization in Mitigating Pain II